why ChromaDex Corporation [CDXC] is a Good Choice for Investors After New Price Target of $16.00

ChromaDex Corporation [NASDAQ: CDXC] closed the trading session at $9.86 on 04/06/21. The day’s price range saw the stock hit a low of $9.82, while the highest price level was $10.87. The company report on March 31, 2021 that ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

ChromaDex External Research Program (CERP) and the Citrin Foundation to collaborate on series of studies exploring rare disease citrullinemia.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .


ChromaDex Corp. (NASDAQ: CDXC) announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen® nicotinamide riboside (NR) and citrin deficiency, a rare genetic condition. In collaboration with the ChromaDex External Research Program (CERP™) and leading research institutions, the Citrin Foundation will fund a series of preclinical and clinical studies to explore the potential impact of increased NAD+ levels on patients with citrin deficiency. The first study, led by Prof. Paul M. Yen and other scientists at Duke-NUS Medical School in Singapore, will examine the ability of NR to impact mitochondrial function, lipid accumulation, inflammation, and fibrosis in the liver using preclinical models of citrin deficiency.

The stocks have a year to date performance of 105.42 percent and weekly performance of 14.92 percent. The stock has been moved at 150.89 percent over the last six months. The stock has performed -8.11 percent around the most recent 30 days and changed 107.58 percent over the most recent 3-months.

If compared to the average trading volume of 3.82M shares, CDXC reached to a volume of 1057609 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about ChromaDex Corporation [CDXC]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CDXC shares is $16.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CDXC stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Oppenheimer have made an estimate for ChromaDex Corporation shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on October 16, 2019. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on February 14, 2019, representing the official price target for ChromaDex Corporation stock. Previously, the target price had yet another raise from $6 to $8, while H.C. Wainwright kept a Buy rating on CDXC stock.

The Average True Range (ATR) for ChromaDex Corporation is set at 1.94, with the Price to Sales ratio for CDXC stock in the period of the last 12 months amounting to 10.69. The Price to Book ratio for the last quarter was 36.52, with the Price to Cash per share for the same quarter was set at 0.26.

CDXC stock trade performance evaluation

ChromaDex Corporation [CDXC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.92. With this latest performance, CDXC shares dropped by -8.11% in over the last four-week period, additionally plugging by 150.89% over the last 6 months – not to mention a rise of 198.79% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CDXC stock in for the last two-week period is set at 49.68, with the RSI for the last a single of trading hit 48.49, and the three-weeks RSI is set at 51.18 for ChromaDex Corporation [CDXC]. The present Moving Average for the last 50 days of trading for this stock 8.94, while it was recorded at 9.72 for the last single week of trading, and 5.85 for the last 200 days.

ChromaDex Corporation [CDXC]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and ChromaDex Corporation [CDXC] shares currently have an operating margin of -18.99 and a Gross Margin at +59.53. ChromaDex Corporation’s Net Margin is presently recorded at -33.62.

Return on Total Capital for CDXC is now -55.96, given the latest momentum, and Return on Invested Capital for the company is -102.83. Return on Equity for this stock declined to -108.09, with Return on Assets sitting at -50.70. When it comes to the capital structure of this company, ChromaDex Corporation [CDXC] has a Total Debt to Total Equity ratio set at 9.97. Additionally, CDXC Total Debt to Total Capital is recorded at 9.06, with Total Debt to Total Assets ending up at 4.27. Long-Term Debt to Equity for the company is recorded at 6.19, with the Long-Term Debt to Total Capital now at 5.63.

Reflecting on the efficiency of the workforce at the company, ChromaDex Corporation [CDXC] managed to generate an average of -$181,136 per employee. Receivables Turnover for the company is 24.34 with a Total Asset Turnover recorded at a value of 1.51.ChromaDex Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 2.00.

Earnings per share (EPS) analysis for ChromaDex Corporation [CDXC] stock

With the latest financial reports released by the company, ChromaDex Corporation posted -0.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CDXC.

ChromaDex Corporation [CDXC]: Insider Ownership positions

There are presently around $156 million, or 24.00% of CDXC stock, in the hands of institutional investors. The top three institutional holders of CDXC stocks are: BLACKROCK INC. with ownership of 2,896,873, which is approximately 3.292% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 2,438,556 shares of the stock with an approximate value of $24.04 million in CDXC stocks shares; and ICONIQ CAPITAL, LLC, currently with $16.83 million in CDXC stock with ownership of nearly 0% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in ChromaDex Corporation stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 45 institutional holders increased their position in ChromaDex Corporation [NASDAQ:CDXC] by around 1,233,461 shares. Additionally, 33 investors decreased positions by around 674,059 shares, while 14 investors held positions by with 13,926,974 shares. The mentioned changes placed institutional holdings at 15,834,494 shares, according to the latest SEC report filing. CDXC stock had 16 new institutional investments in for a total of 264,299 shares, while 12 institutional investors sold positions of 389,402 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.